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Ribavirin is the first synthetic, broad-spectrum antiviral nucleoside. Despite its more than 30 year history, the mechanism
of action of this compound remains unclear and somewhat controversial. Recent data suggest the possibility that the activity
of ribavirin against RNA viruses is a reflection of incorporation of ribavirin into the viral genome. Because ribavirin
incorporation is not specific, this event leads to lethal mutagenesis of the virus population. The data supporting this newewed h
ive antMECHANISMS OF ACTION OF RIBAVIRIN
Ribavirin (1--D-ribofuranosyl-1,2,4-triazole-3-carboxamide,
also known as virazole) is the first synthetic, broad-spec-
trum antiviral nucleoside (Fig. 1) (Sidwell et al., 1972). It is
currently used clinically in combination with interferon- for
treatment of hepatitis C virus (HCV) infection (Cummings
et al., 2001; Di Bisceglie et al., 2001) and as a monotherapy
for treatment of Lassa fever virus (Andrei and De Clercq,
1993; Huggins, 1989) and respiratory syncytial virus (Krilov,
2001) infections. Ribavirin is administered as the nucleo-
side. Once in the cell, ribavirin is rapidly converted to
ribavirin monophosphate (RMP) by adenosine kinase. Se-
quential phosphorylation leads to the formation and accu-
mulation of ribavirin triphosphate (RTP).
While ribavirin exhibits antiviral activity against a wide
range of DNA and RNA viruses in the laboratory, the
mechanism of action of this compound is still debated.
Ribavirin monophosphate has been shown to be an inhibi-
tor of inosine monophosphate dehydrogenase (IMPDH),
a cellular enzyme required for the de novo synthesis
of guanosine triphosphate (GTP) (Muller et al., 1977;
Streeter et al., 1973). Treatment of cells with ribavirin
results in a twofold reduction in intracellular GTP (Muller
et al., 1977). Because GTP is required for translation,
transcription, and/or replication of all viruses, subtle re-
ductions in the cellular GTP pool could account for the
broad-spectrum antiviral activity of ribavirin.
Although current dogma maintains IMPDH as the tar-175get for the antiviral activity of ribavirin, not all IMPDH
inhibitors possess antiviral activity (Crotty et al., 2000;
Lanford et al., 2001). Over the past 30 years, several
alternative hypotheses for the antiviral activity of ribavirin
have been put forward, including inhibition of capping of
viral RNA transcripts (Scheidel and Stollar, 1991), direct
inhibition of the viral RNA polymerase (Eriksson et al.,
1977), and modulation of the host immune response
(Fang et al., 2000; Zuckerman et al., 2001). In addition, it
has been suggested that the antiviral activity of ribavirin
may reflect direct incorporation into RNA. Indeed, RTP
accumulates to high levels in some tissues (Zimmerman
and Deeprose, 1978). However, attempts to demonstrate
incorporation into viral RNA by using radiolabeled riba-
virin have been unsuccessful, suggesting very low or no
incorporation into RNA.
Recently, a novel primer-extension assay which uti-
lizes end-labeled primers was developed to monitor the
activity of poliovirus RNA-dependent RNA polymerase
(RdRP) (Arnold and Cameron, 2000). When this assay
was employed to evaluate utilization of RTP by poliovirus
polymerase, direct incorporation of ribavirin into RNA
was observed (Crotty et al., 2000). In general, the maxi-
mal rate of incorporation of ribavirin was equivalent to
that of an incorrect nucleotide, 0.014–0.019/s. This value
is 3000- to 6000-fold slower than that measured for
incorporation of a correct nucleotide in this context.
Therefore, less than three molecules of ribavirin will be
incorporated per genome per replication cycle, and the
actual value will be dependent upon the intracellular
concentration of RTP. The apparent binding constant forproposal for the mechanism of action of ribavirin are revi
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cytidine and uridine. This promiscuous basepairing ca-
pacity of ribavirin is likely due to the two different con-
figurations assumed by the carboxamide moiety of the
pseudobase of ribavirin (Fig. 1). Additional experiments
with RNA containing ribavirin confirmed that ribavirin
templates incorporation of cytidine and uridine with
equal efficiency. The ability of ribavirin to basepair with
both cytidine and uridine suggests that ribavirin should
increase the frequency of transition mutations in the viral
genome.
It is known that poliovirus replication is inhibited by the
presence of 2 mM guanidine and that resistance to
guanidine is conferred by a single transition mutation in
the viral 2C-coding region (Baltera and Tershak, 1989).
Replication in the presence of guanidine requires a C to
U transition that occurs naturally in the poliovirus popu-
lation at a frequency of 105. If ribavirin is an RNA virus
mutagen, then by growing virus in the presence of this
compound an increase in the occurrence of guanidine-
resistant virus in the population would be expected.
Indeed, increasing the ribavirin concentration in which
virus was grown resulted in a dose-dependent increase
of guanidine-resistant variants in the population. These
data provide further support for the ability of ribavirin to
act as a mutagen (Crotty et al., 2000). This new mecha-
nism of action for ribavirin is illustrated schematically in
Fig. 2. It is worth noting that lethal mutagenesis may also
be the operative mechanism for the anti-HCV activity of
ribavirin as the HCV RdRP incorporates ribavirin oppo-
site cytidine and uridine with equal efficiency (Maag et
al., 2001).
FIG. 1. Ribavirin exhibits promiscuous basepairing capacity. Rotation
of the carboxamide moiety of the pseudobase permits hydrogen bond-
ing to both cytosine and uracil. “R” denotes ribose.
FIG. 2. Ribavirin incorporation increases the mutation rate of RNA viruses. A typical poliovirus replication cycle results in approximately 1.5
mutations per progeny genome (left). Infection in the presence of 400 M ribavirin (right) results in approximately 6.9 mutations per genome and a
reduction in viral fitness to 5% of the wild-type population (Crotty et al., 2001). Ribavirin monophosphate is an IMPDH inhibitor, resulting in a twofold
reduction of cellular GTP, while the triphosphate (RTP) can be incorporated directly into viral RNA.
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QUASISPECIES AND ERROR CATASTROPHE
Given that ribavirin incorporation into the poliovirus
genome is mutagenic, the question arises: how suscep-
tible is poliovirus to the accumulation of additional mu-
tations? Poliovirus polymerase, similar to other RdRPs,
lacks a proofreading activity, causing the virus to exist as
a quasispecies—that is, an extremely heterogeneous
population in which each member differs from another by
a finite number of changes in the viral genome (Domingo
et al., 1985). Although the use of the term quasispecies
by virologists as it relates to RNA virus evolution has
been challenged (Holmes and Moya, 2002), the concept
as applied by virologists has led to significant contribu-
tions in understanding the RNA virus lifecycle and patho-
genesis (Domingo, 2002). The quasispecies nature of
RNA viruses produces a spectrum of phenotypic variants
which can rapidly evolve in response to changing envi-
ronmental conditions such as the host immune response
or clinical intervention.
However, there must be some level of “diversity” in
which the virus is forced into error catastrophe—that is,
the point at which the number of mutations per genome
is too large for viability. Error catastrophe theory predicts
that once the error threshold is reached, even a slight
increase in mutation frequency should cause a dramatic
reduction in virus viability. RNA viruses should be partic-
ularly sensitive to mutation because their genomes are
so informationally dense, encoding gene products as
well as RNA structural signals for translation and repli-
cation. If increased genetic diversity is an important
contributor to the fitness of an RNA virus population, then
it is likely that viruses have evolved to exist on the
threshold of error catastrophe—that is, the point of max-
imal adaptability.
Crotty and colleagues have exploited ribavirin mu-
tagenesis to evaluate the effect of mutations on the
fitness of poliovirus (Crotty et al., 2001). The normal
poliovirus population has approximately 1.5 mutations
per genome based upon sequence analysis of several
genome equivalents of capsid-coding sequence. By
growing poliovirus in a range of ribavirin concentrations,
the mutation frequency could be increased to 10-fold
greater than that of the normal population. The specific
infectivity of RNA containing the random mutations was
measured and plotted vs the average number of muta-
tions per genome (Fig. 3). A dramatic decrease in infec-
tivity was observed when the mutation frequency ex-
ceeded approximately two mutations per genome. This
graph suggests that poliovirus has evolved to exist on
the threshold of error catastrophe and proves that riba-
virin can have a direct effect on viral RNA.
The recent development of a tamarin hepatocyte tis-
sue culture system for GB virus B (GBV-B), a close rela-
tive of HCV, has provided further evidence for the incor-
poration of ribavirin into viral RNA (Lanford et al., 2001).
Pretreatment of cells with 100 M ribavirin prior to infec-
tion resulted in an almost 104-fold decrease in cell-
associated viral RNA after infection. In agreement with
data obtained for poliovirus, the specific infectivity of
GBV-B RNA was decreased substantially by growth of
virus in the presence of ribavirin.
Together, these new data support the idea that ribavi-
rin is a lethal mutagen of RNA virus genomes. However,
these studies failed to demonstrate extinction of the virus
population by using ribavirin. The concept of lethal mu-
tagenesis is not a new one. Holland and co-workers
recognized first that small (less than threefold) increases
in mutation frequency were sufficient to cause a signifi-
cant reduction in virus viability by using both poliovirus
and vesicular stomatitis virus as model systems (Holland
et al., 1990). Extinction of virus populations in the pres-
ence of mutagens has been documented in a number of
systems. Loeb and colleagues found that a slight in-
crease in mutation frequency of human immunodefi-
ciency virus resulted in a significant reduction in virus
viability. Moreover, serial passage of the virus in the
presence of a mutagen that increased the mutation fre-
quency only threefold was sufficient for viral extinction
(Loeb and Mullins, 2000). Domingo and colleagues dem-
onstrated efficient extinction of foot-and-mouth disease
virus in the combined presence of a mutagen (5-fluoro-
uracil) and viral inhibitor (guanidine) without observing
an increase in mutations conferring resistance to the
inhibitor (Pariente et al., 2001).
FIG. 3. The normal poliovirus population exists on the threshold of
error catastrophe. Specific infectivity of poliovirus RNA was set at 100%;
RNA produced by in vitro transcription of a cDNA clone shows a subtle
increase in specific infectivity relative to RNA isolated from virions. The
LI50 (50% loss of specific infectivity) is defined as the mutation fre-
quency at which 50% of viral genomes are lethally mutated. Wild-type
(wt) poliovirus genomes contain an average of 1.5 mutations. Poliovirus
genomes isolated from cells treated with 100, 400, or 1000 M ribavirin
contain 1.9, 6.9, or 15.5 mutations, respectively. Reproduced with per-
mission from Crotty et al., Copyright 2001, National Academy of Sci-
ences, U.S.A.
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The utilization of ribavirin as a substrate by the viral
RdRP can explain the effectiveness of ribavirin against a
diverse range of RNA viruses as the polymerase repre-
sents a common enzyme for these viruses. However, the
proposed mechanisms of action for ribavirin are not
mutually exclusive. Because ribavirin can compete with
GTP for basepairing with UTP, a decrease in cellular GTP
pools would be expected to favor incorporation of RTP as
a GTP analog. In fact, reduction in the GTP pool may be
necessary for efficient utilization of ribavirin. Additionally,
incorporation of a base analog by the RdRP can have
deleterious effects other than direct mutagenesis. For
example, direct incorporation of ribavirin into RNA may
impair codon–anticodon recognition during translation or
disrupt Hoogsteen basepairing necessary for RNA struc-
ture. Another possibility is that ribavirin may utilize dif-
ferent modes of action against different viruses. For ex-
ample, the primary target of ribavirin against Sindbis
virus is the guanylyl transferase activity as ribavirin-
resistant variants contain changes in guanylyl-trans-
ferase-coding sequence (Scheidel and Stollar, 1991).
LETHAL MUTAGENESIS AS AN ANTIVIRAL
STRATEGY
If the data obtained for poliovirus and GBV-B hold true
for other RNA viruses, then an analog causing a small
increase in mutation frequency may be sufficient to drive
other viruses into error catastrophe. How do we translate
these findings for ribavirin into novel and more effective
antiviral therapies? Examination of the nucleoside base
suggests two categories of mutagenic nucleosides:
those with ambiguous basepairing capacity (i.e., hydro-
gen-bonding); and those with ambiguous interaction ca-
pacity that do not rely on hydrogen bonding. Both types
of molecules are referred to as universal bases (Loakes,
2001).
The latter has no basepairing properties but forms
stable duplexes in DNA or RNA irrespective of the par-
ticular base against which it is paired. Stability is
achieved through base-stacking interactions due to the
hydrophobic character of the aromatic base residue. An
example of this type of pseudobase is 3-nitropyrrole
(3-NP) (Fig. 4A). The utility of 3-NP as a nonspecific
analog for DNA probes and primers has been well doc-
umented in the laboratory (Loakes, 2001). However, the
effectiveness of non-hydrogen-bonding, universal ribo-
nucleosides as antiviral agents remains to be tested. It is
possible that hydrogen-bonding interactions are essen-
tial for recognition by the RdRP for incorporation of these
analogs into the genome at a high enough rate to induce
lethal mutagenesis.
A good example of an ambiguous, hydrogen-bonding
analog is nucleoside P (Fig. 4B). This pseudobase pairs
with both adenosine and guanosine and has been
shown to increase mutation frequency in an in vitro
retroviral replication model (Lin and Brown, 1989;
Moriyama et al., 2001). Furthermore, as a pyrimidine
analog, this compound may potentially be required at a
lower level than purine analogs because the competing
intracellular pyrimidine pool is much lower than that of
purines (Traut, 1994).
In light of the findings for ribavirin, it may be worth-
while to evaluate other known antiviral compounds for
mutagenic potential. A number of established antivirals
are nucleoside analogs and are known to be phosphor-
ylated to the triphosphate by cellular enzymes, but their
antiviral activity has been attributed to inhibition of nu-
cleotide biosynthesis (De Clercq, 1993). For instance,
pyrazofurin is a nucleoside analog with a structure sim-
ilar to ribavirin (Fig. 4C). It has demonstrated antiviral
activity attributed to the monophosphate’s ability to in-
hibit cellular ovotidine monophosphate (OMP) decarbox-
ylase, an enzyme required for pyrimidine biosynthesis
(Cadman et al., 1978; Dix et al., 1979). All OMP decar-
boxylase inhibitors are not antivirals, a situation reminis-
cent of that for ribavirin (Rada and Dragun, 1977). It may
be possible that viral polymerases are able to effectively
utilize the triphosphate of pyrazofurin for incorporation
into RNA. The structure of pyrazofurin indicates that it too
may have ambiguous basepairing interactions. It is
known that the triphosphate accumulates in cells treated
with the nucleoside (Zimmerman and Deeprose, 1978).
Development of mutagenic nucleosides for clinical
use requires not just utilization of the compound by the
FIG. 4. Examples of potentially mutagenic nucleosides. (A) 3-nitro-
pyrrole is a universal non-hydrogen-bonding pseudobase. (B) Nucleo-
side P can tautomerize to basepair with adenine or guanine. (C)
Pyrazofurin is a known antiviral with a structure similar to ribavirin-
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RdRP but also consideration of cellular toxicity and clin-
ical side effects. The cellular enzyme ribonucleotide re-
ductase is required for conversion of ribonucleotides to
deoxyribonucleotides. Nucleoside analogs containing
modified sugar residues may be able to escape recog-
nition by this enzyme and hence be unable to participate
in DNA replication, eliminating the possibility of long-
term and heritable changes to the host genome. Toxicity
is often also attributed to changes in cellular nucleoside
triphosphate (NTP) pools by inhibition of nucleotide bio-
synthesis. Sugar modification may also prevent these
analogs from affecting such metabolic pathways. How-
ever, intracellular phosphorylation to the triphosphate by
host kinases is required for incorporation. This obstacle
can be overcome synthetically by chemical phosphory-
lation and protection to permit delivery into cells and
activation therein (Wagner et al., 2000). Designing a mol-
ecule that can be incorporated into viral genomes with-
out affecting cellular NTP pools and host replication will
prove challenging because our current understanding of
substrate recognition by enzymes involved in nucleotide
metabolism is very limited.
In summary, recent studies of the antiviral mecha-
nisms of ribavirin offer support for a new class of antivi-
rals—namely, lethal mutagens. Identification of muta-
genic nucleosides that can escape recognition by cellu-
lar enzymes and be utilized by the viral polymerase will
be required to pursue this strategy for antiviral therapy.
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